A 24-week, Open-label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-23) Switched From Cholinesterase Inhibitors (Donepezil, Galantamine)

Trial Profile

A 24-week, Open-label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-23) Switched From Cholinesterase Inhibitors (Donepezil, Galantamine)

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2015

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 11 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Oct 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 09 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top